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Cell Transplantation to Restore Lost
Auditory Nerve Function is a Realistic
Clinical Opportunity
Tetsuji Sekiya1,2 and Matthew C. Holley3
Abstract
Hearing is one of our most important means of communication. Disabling hearing loss (DHL) is a long-standing, unmet
problem in medicine, and in many elderly people, it leads to social isolation, depression, and even dementia. Traditionally,
major efforts to cure DHL have focused on hair cells (HCs). However, the auditory nerve is also important because it
transmits electrical signals generated by HCs to the brainstem. Its function is critical for the success of cochlear implants as
well as for future therapies for HC regeneration. Over the past two decades, cell transplantation has emerged as a promising
therapeutic option for restoring lost auditory nerve function, and two independent studies on animal models show that cell
transplantation can lead to functional recovery. In this article, we consider the approaches most likely to achieve success in the
clinic. We conclude that the structure and biochemical integrity of the auditory nerve is critical and that it is important to
preserve the remaining neural scaffold, and in particular the glial scar, for the functional integration of donor cells. To exploit
the natural, autologous cell scaffold and to minimize the deleterious effects of surgery, donor cells can be placed relatively
easily on the surface of the nerve endoscopically. In this context, the selection of donor cells is a critical issue. Nevertheless,
there is now a very realistic possibility for clinical application of cell transplantation for several different types of hearing loss.
Keywords
auditory nerve, cell transplantation, glial scar, nerve regeneration, scaffold.
Introduction
Over 450 million people suffer disabling hearing loss
(DHL), equivalent to 6.1% of the world’s population
(https://www.who.int/deafness/estimates/en/). Hearing loss
affects our most important means of communication, and it
may lead to social isolation, depression, and even dementia
in the elderly1.
Traditionally, significant efforts to cure DHL have focused
on hair cells (HCs). No less important, however, is the audi-
tory nerve, which contains the sensory neurons that transmit
electrical signals generated by HCs to the brainstem2,3.
Auditory nerve damage may occur as a result of various
types of insult. These include internal causes, such as neu-
ropathies and intracranial mass lesion, and head trauma,
which is a representative external cause3. Over several
decades, cell transplantation has emerged as a promising
therapeutic option to rebuild lost auditory nerve function.
Numerous studies in vitro and in vivo have explored differ-
ent combinations of cells and delivery methods, and two
successful studies have provided proof of principle that cell
transplantation can lead to functional recovery. The
challenge now is to focus on how the human auditory system
can be approached in the clinic, including the selection of
donor cells and how auditory nerve function can be restored
with surgically acceptable techniques involving minimal
intervention.
Degeneration Pattern of Auditory Neurons Following Insult
Insight into why cell transplantation works comes from the
nature of tissue degeneration (Fig. 1). When auditory nerve
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axons are compromised, for example, in neuropathies,
closed head injury, microsurgery (MiS), or radiation expo-
sure in radiotherapy (RT) (see the following section), degen-
eration proceeds centripetally away from the soma, as in
Wallerian or anterograde degeneration (Fig. 1B, j).
Cochlear nucleus cells and upper neurons up to the cerebrum
subsequently degenerate transneuronally4 (Fig. 1B, k). At
the same time, retrograde axon degeneration proceeds
toward the soma of spiral ganglion cells (SGCs) within the
cochlea, leading eventually to the death of the neurons and
loss of the peripheral processes (Fig. 1B, l). If auditory
neurons degenerate, the HCs that they innervate can still
survive. Auditory neurons express the tyrosine receptor
kinase B (TrkB) and tyrosine kinase receptor C (TrkC) (Fig.
1A) for brain-derived neurotrophic factor (BDNF) and neu-
rotrophin 3 (NT-3), which are produced mainly by HCs3,5.
Thus, damage to HCs can lead to degeneration of auditory
neurons and transneuronal degeneration of the cochlear
nucleus cells and upper relay neurons (Fig. 1, m, k)3. It is
well known clinically that degeneration of the HCs is trig-
gered by systemic use of pharmacological agents such as
aminoglycoside antibiotics and platinum-based drugs6 and
also exposure to intense noise7.
Hearing levels can deteriorate progressively in closed
head injury patients8. Similarly, in MiS and RT for vestibular
schwannoma (VS), the hearing preservation rates measured
within a few years of treatment can be misleading because
hearing loss that is unrelated to tumor recurrence continues
to progress even after 7 to 8 years9–14. Various mechanisms
are responsible for such delayed hearing loss, but one con-
tributing factor is likely to be the unusually slow speed of
auditory nerve degeneration, which can be protracted for
years15. There are several reasons for the slow degeneration
of the auditory nerve. First, the soma of human SGCs contact
each other and can provide mutual trophic support16. Sec-
ond, non-myelinated Schwann cells (SCs) and satellite glial
cells surrounding the soma prevent the SGCs from dying
even after HCs are damaged17. Third, SGCs depend on neu-
rotrophins provided mainly by HCs but supporting cells are
also a source of neurotrophins18 even after the HCs degen-
erate. Cochlear implants (CIs) stimulate auditory neurons
directly and they exploit the protracted course of auditory
nerve degeneration15. Cell transplantation is more likely to
succeed for the same reason because degenerated auditory
neurons can be replenished progressively by donor cell-
derived neurites that seem to regenerate over several
months2.
Causes of Auditory Nerve Degeneration and Related
Clinical Issues
Neuropathies. The classical description of auditory neuropa-
thy (AN) is that auditory nerve function is impaired but outer
HCs in the cochlea are functional19. In AN, speech compre-
hension is compromised although pure tone audiograms are
disproportionately well maintained so patients can hear but
cannot understand19. This type of hearing loss is observed in
various diseases including a subset of neuropathic and pres-
bycusis patients20,21. Nowadays, the causative sites for AN
include not only the auditory nerve and outer HCs but also
the inner HCs and inner HCs ribbon synapses (auditory
synaptopathy)19. Nevertheless, AN due to auditory nerve
dysfunction and auditory neuropathic hearing loss is a poten-
tial candidate for cell transplantation2,3,22. Some patients
with genetic disorders have polyneuropathic disorders, such
as auditory neuropathic hearing loss and optic neuropathy
with bilateral blindness20, and their anguish would be alle-
viated remarkably even if only their hearing was restored.
For patients with pathologies in both the auditory nerve and
Figure 1. Auditory neurons and their degeneration patterns. (A)
The auditory nerve is a bundle of bipolar auditory neurons. The
peripheral processes of auditory neurons form synapses with HCs
and the central processes with CNs in the brainstem. HCs provide
much of the trophic support required for the maintenance and
survival of auditory neurons, including BDNF and NT-3. Auditory
neurons synthesize the high-affinity tyrosine receptor kinases, TrkB
and TrkC. The interface between the PNS and CNS is called the
TZ, which is distal to the IAM. Myelin sheaths are formed by
oligodendrocytes centrally from the TZ, and the surrounding
milieu is astrocytic. Peripheral to the TZ, the myelin sheaths are
formed by Schwann cells that are enveloped in endoneurium. The
interface is penetrated only by axons. (B) The onset of anterograde
(Wallerian) (j), trans-neuronal (k), and retrograde degeneration
(l) of the auditory nerve depends on the initial site of injury (x). In
HC damage, neurodegeneration involves the auditory neuron
entirely (m) and neurodegeneration proceeds to higher-level
neurons including the CNs (k). Shaded arrows indicate the
progression of degeneration, and dotted arrows indicate
transneuronal degeneration. BDNF, brain-derived neurotrophic
factor; CNS, central nervous system; CNs, cochlear nucleus cells;
HC, hair cells; IAM, internal auditory meatus; NT-3, neurotrophin
3; PNS, peripheral nervous system; TZ, transitional zone.
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HCs, auditory nerve regeneration would most effectively be
coupled with HC regeneration, should that eventually prove
to be successful in mammals.
Tumors. VS develops from the vestibular nerve, but the sur-
gical removal of VS inevitably imposes direct mechanical
stress to the auditory nerve, potentially leading to the sever-
ance of continuity of auditory neurons or to the initiation of
auditory nerve degeneration. VS surgery can also have far-
reaching effects on the cochlea through the vasculature (the
internal auditory artery or labyrinthine artery), leading to
cochlear ischemia and reflow phenomena that are inevitably
repeated during surgery, eventually leading to HC death. The
latter presumption is supported by recordings of distortion
product otoacoustic emissions (DPOAEs), which are sounds
generated within the cochlea recorded by a microphone
fitted into the ear canal23. The amplitude of DPOAEs reflects
the blood flow to the cochlea24, and an intraoperative
decrease in DPOAEs indicates cochlear ischemia due to
mechanical pressure upon the vasculature25,26. Several min-
utes of cochlear ischemia are sufficient to cause morpholo-
gical changes of the distal ends of the auditory neurons, and
longer periods can cause cessation of internal auditory artery
blood flow leading to HC death27,28. Postmortem histologi-
cal examinations of VS patients without surgery reveal struc-
tural changes within the cochlea, including degeneration of
HCs and the stria vascularis in the outer wall of the scala
media29.
Radiation. Radiotherapy (RT) for the central nervous system
(CNS) and peripheral nervous system (PNS) lesions incur
multiple pathological processes, including vascular endothe-
lial damage, neuroinflammation, genetic/epigenetic altera-
tions, apoptosis/necrosis of neurons and glial cells, reactive
gliosis, and demyelination and deterioration of stem cell and
progenitor cell proliferation30. It is extremely difficult to
avoid radiation injury to the auditory nerve in RT for
VS31. To make matters worse, not only the cochleovestibular
nerve but also the facial nerve and other vital structures, such
as HCs and the stria vascularis32, are packed in a confined
space of the cochlea (Fig. 2). The horizontal diameter of the
internal auditory canal is only about 4.5 mm33. Within this
narrow canal, the cochleovestibular and facial nerves are
compressed by the tumor and take a tortuous course. Reports
revealed that radiation doses in the cochlea and cochlear
nucleus during RT are correlated with patients’ hearing out-
come31,34, implying radiation injury to auditory neurons is
responsible for hearing deterioration after RT in addition to
that to HCs and the stria vascularis, both vital to hearing32.
Patients with small VS in which auditory neurons degenerate
but HCs are still functional35 are an ideal candidate for audi-
tory nerve replacement3, and this is the case in a subset of
presbycusis or auditory neuropathic patients as mentioned
above20,21.
Head Injury. In patients with a closed head injury even with-
out temporal bone fractures, damage to auditory neurons is
observed primarily and/or secondarily following HC
Figure 2. Reported cell delivery methods to restore AuN func-
tion. (A) Reported cell delivery methods in Table 1 are shown with
arrows in the upper panel. Dark shaded parts of each arrow indi-
cate intracochlear or intraneural portions of each route. Arrows
show each route conceptually and do not trace each anatomical
route precisely. The dotted rectangle is enlarged to illustrate intra-
cochlear structures in detail. (B) Surface transplantation of DCs on
degenerated AuN. DCs transplanted onto the surface of degener-
ated AuN autonomously enter the nerve, differentiate (*) and form
functional synapses with HCs and CNs (#). In degenerated AuN,
the AO and SC columns form a continuous, “naturally occurring
autologous cell bridge”, the AO–SC complex (a part is shown
here), which acts as an anatomical scaffold for DC migration to
connect between the PNS and the CNS (see the text). Note regen-
erating axons run parallel with the AO–SC complex. Studies using
systemic delivery of donor cells are not shown here. AO, astrocyte
outgrowth; AuN, auditory nerve; CNS, central nervous system;
CN, cochlear nucleus cell; CPA, cerebellopontine angle; DC, donor
cells; HC, hair cell; IAC, internal auditory canal; IAM, internal audi-
tory meatus; IHC, inner hair cell; OHC, outer hair cell; MLI, mem-
branous labyrinth injured; MLP, membranous labyrinth preserved;
PNS, peripheral nervous system; RC, Rosenthal’s canal; ScM, the
scala media; SC, Schwann cell; ScT, the scala tympani; ScV, the scala
vestibuli; SuC, supporting cell; TZ, the transitional zone.
Sekiya and Holley 3
damage36–42. Clinically, cases in which the auditory nerve is
damaged without damage to HCs are most suitable for cell
transplantation because the HCs can provide trophic support,
as mentioned above (Fig. 1). The auditory nerve is particularly
vulnerable to external force in the regions of the fundus of the
internal auditory canal and the transitional zone (TZ)36–41.
When the medial displacement of the brainstem is greater than
that of the cochlea in the temporal bone, the resultant force on
the auditory nerve may avulse the auditory neurons from the
fundus of the internal auditory canal36–41. The TZ is the inter-
face between the CNS and PNS43, and it can be highlighted by
immunostaining for glial fibrillary acidic protein (GFAP),
which is expressed by astrocytes only in the CNS2 and it lies
within the internal auditory canal44 (Fig. 3). The TZ is vul-
nerable to external stretch and shear forces probably because
there is an abrupt anatomical change at this point; central to
the TZ, myelin sheaths are formed by oligodendrocytes, and
the supporting tissue is astrocytic, whilst peripheral to the TZ,
the sheaths are SCs enveloped in endoneurium, although the
axons are continuous3,39. HC damage in closed head injury
may occur due to a breach of the sealing of the membranous
labyrinth and/or impairment of blood supply to the cochlea42.
Cochlear Implants (CIs)
Cell transplantation could potentially enhance the perfor-
mance and candidature for CI in patients, who generally
have too few remaining functional auditory neurons45,46.
In fact, the minimum number of functional auditory neurons
needed for the successful performance of a CI is astonish-
ingly few and estimated to be 5% to 10% of the normal
number15. CIs are beneficial to neurofibromatosis type 2
(NF2) patients with bilateral VS47, but a significant number
of patients experience a decline in performance as the VS
grows48. Hence, replenishing auditory neurons would poten-
tially benefit NF2 patients.
Surgical Options for Cell Delivery
There is extensive literature on cell transplantation to the
auditory system, but in this context, the relevant studies are
those done in vivo on deafened animals and on deaf humans
(Table 1). To establish proof of principle, two main conditions
must be met in the analysis of cell integration and functional
recovery49. First, there must be an electrophysiological anal-
ysis of the restoration of nerve function with an objective
method such as the auditory brainstem response (ABR). Sec-
ond, to link recovery to the transplanted cells, it is important to
provide morphological evidence for synaptic connections, not
only with HCs in the cochlea but also with neurons of the
cochlear nuclei within the brainstem. In other parts of the
nervous system, functional improvements have been recorded
without morphological integration of the donor cells50–52 by
indirect mechanisms, including trophic effects, immunomo-
dulation, and other bystander effects53–55.
Equally important from the experimental aspect are clin-
ical relevance, which is reflected in the animal model used to
replicate human clinical pathology, and clinical feasibility,
which relates to whether or not the surgical techniques can
be used in the clinic. In the following sections, we consider a
number of in vivo studies in these terms. We focus on local
delivery of cells to parts of the inner ear because trials with
systemic cell delivery have not led to successful migration of
donor cells to the auditory system56–64 (Table 1).
Cell Delivery into the Cochlea with Injury to the Membranous
Labyrinth. The soma of spiral ganglion neurons (SGNs) are
located within the cochlea, and it is worth knowing whether
or not cells delivered into the cochlear fluid spaces or
cochlear wall are able to find their way into Rosenthal’s
canal in which the SGN soma are housed (Fig. 2A). This
does not seem to be the case, and none of the relevant studies
have led to functional recovery (Table 1). With the exception
of two studies65,66, the membrane that seals intracochlear
fluid-containing spaces (the membranous labyrinth ¼ the
scala tympani, scala vestibuli, the scala media, and posterior
semicircular canal) was breached and/or trespassed (mem-
branous labyrinth injured [MLI])67–92 (Table 1). Impor-
tantly, invasion into the membranous labyrinth is clinically
unacceptable because it leads to hearing loss3. Furthermore,
the cochlea in small experimental animals is easily accessi-
ble as it is conspicuous within the hollow dome-like bulla,
but it is not as accessible in humans as it is deeply buried in
Figure 3. Transitional zone and the astrocyte outgrowth following
auditory nerve mechanical compression. (A) Normal TZ. The CNS
portion of the AuN extends peripherally, with a dome-like shape
(arrowheads with dotted line). Rosenthal’s canals are densely
packed with auditory SGC (arrows). Rat, Hematoxylin and Eosin
stain, Scale bar, 200 mm. Cited from Sekiya et al. (2007) with pub-
lisher’s permission. (B) Gliotic AuN after compression. A glial scar
is induced following mechanical compression applied to the CNS
portion of the auditory nerve in the cerebellopontine angle (arrow-
heads). Marked AO is indicated by double arrows. Most auditory
SGCs degenerate following sustained compression (single arrows
in dotted circle, Rosenthal’s canal). With GFAP antibody, an astro-
cyte marker, the glial scar is also stained because it contains many
reactive astrocytes. An antibody Tuj1 against beta-tubulin stains
neurons and neurites, including SGCs. The curved dotted line indi-
cates the default position of the TZ. (Inset) Normal rat AuN. The
TZ (arrows) is clearly observed as a peripherally convex, dome-like
shape. The PNS portion of the nerve (outlined by dotted line) is
GFAP-negative because astrocytes exist only in the CNS. Scale
bars, 200 mm. AO, astrocyte outgrowth; AuN, auditory nerve;
CNS, central nervous system; GFAP, glial fibrillary acidic protein;
IAM, internal auditory meatus; PNS, peripheral nervous system;
SGCs, spiral ganglion cells; TZ, transitional zone.
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Table 1. In vivo studies to restore auditory nerve function.
Study








Cell delivery into the cochlea




Hu et al. (2005)78 ditto Guinea pig
Pharmacol, local
No Mouse ESC and DRGC
Hu et al. (2005)80 ditto Guinea pig
Pharmacol, local
No Mouse NSC
Coleman et al. (2006)71 ditto Guinea pig
Pharmacol, systemic**
No Mouse ESC
Matsuoka et al. (2007)86 ditto Gerbil
Pharmacol, local
No Mouse MSC
Parker et al. (2007)87 ditto Mouse/guinea pig
Sound exposure
No Mouse NSC
Altschuler et al. (2008)68 ditto Guinea pig
Pharmacol, systemic
No Mouse ESC
Lang et al. (2008)85 ditto Gerbil
Pharmacol, local
No Mouse ESC
Hu et al. (2009)81 ditto Guinea pig
Pharmacol, systemic
No Mouse DRGC
Cho et al. (2011)70 ditto Guinea pig
Pharmacol, local
No Human MSC
Pettingill et al. (2011)88 ditto Guinea pig
Pharmacol, systemic
No Schwann cells
Warnecke et al. (2012)90 ditto Guinea pig
Pharmacol, systemic
No BDNF-secreting cells
He et al. (2014)76 ditto Guinea pig
Pharmacol, local
No Mouse NSC
Jang et al. (2015)84 ditto Guinea pig
Pharmacol, local
No Human MSC
Fetoni et al. (2014)73 ditto Guinea pig
Noise exposure
No Guinea pig ADSC
Gillespie et al. (2015)74 ditto Guinea pig
Pharmacol, systemic
No BDNF-expressing fibroblast
Jang et al. (2016)83 ditto Guinea pig
Pharmacol, local
No Human ADSC
Xu et al. (2016)92 ditto Rat
Noise exposure
No olfactory epithelium NSC
Dai et al. (2016)72 ditto Rat
Pharmacol, systemic
No Rat OEC
Wise et al. (2016)91 ditto Guinea pig
Pharmacol, systemic
No Human ESC







No Guinea pig ADSC
Huang et al. (2019)82 ditto Gerbil
Pharmacol, local
No Mouse NSC
Hildebrand et al. (2005)77 ScM (MLI) Guinea pig
Pharmacol, systemic
No Mouse ESC
Hu et al. (2005)80 ditto Guinea pig
Pharmacol, local
No Mouse ESC mouse DRGC
Lang et al. (2008)85 ScM, RC (MLI) Gerbil
Pharmacol, local
No Mouse ESC
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Table 1. (continued)
Study








Zhang et al. (2013)65,66 Cochlea wall (MLP) Rat
Pharmacol, local
No Mouse NSC





Direct cell injection into auditory nerve (MLI)
Tamura et al. (2004)101 AuN Mouse
Pharmacol, local
No Mouse NSC
Naito et al. (2004)95 ditto Chinchilla
Pharmacol, systemic
No Bone marrow cell
Hu et al. (2004)94 ditto Rat
Transected AuN
No Mouse DRGC, ESC
Okano et al. (2005)97 ditto Guinea pig
Pharmacol, systemic
No Mouse ESC
Regala et al. (2005)98 ditto Guinea pig, rat
Pharmacol, systemic
No Mouse DRGC
Corrales et al. (2006)93 ditto Gerbil
Pharmacol, local
No Mouse ESC
Matsuoka et al. (2007)86 ditto Gerbil
Pharmacol, local
No Mouse MSC
Shi et al. (2007)100 ditto Gerbil
Pharmacol, local
No Human ESC
Altschuler et al. (2008)68 ditto Guinea pig
Pharmacol, systemic
No Mouse ESC
Reyes et al. (2008)99 ditto Guinea pig
Pharmacol, systemic
No Mouse ESC
Ogita et al. (2010)96 ditto Guinea pig
Pharmacol, local
No Guinea pig MSC-derived spheres
Chen et al. (2012)22 ditto Gerbil
Pharmacol, local
Yes Human ESC
Direct cell injection into the auditory nerve (MLP)
Sekiya et al. (2006)107 AuN Rat Compression of AuN No Mouse ESC
Sekiya et al. (2007)106 ditto ditto No Mouse auditory neuroblast
Palmgren et al. (2012)105 ditto Rat
Pharmacol, local
No Mouse ESC
Jiao et al. (2014)104 ditto Rat
Pharmacol, local
No Human neural precursors
Chen et al. (2019)103 ditto Mouse
Pharmacol, local
No Human limbus-derived MSC
Cell transplantation onto the auditory nerve (MLP)
Sekiya et al. (2015)2 AuN Rat
Compression of AuN
Yes Mouse auditory neuroblast
Systemic delivery (MLP)
Revoltella et al. (2008)63 i.v. Mouse
Pharmacol, systemic
Noise
No Human cord blood stem cells






the temporal bone. Thus, this method is not suitable for
human patients.
Direct Cell Injection Into Auditory Nerve With Injury to the
Membranous Labyrinth. For targeting donor cells to the audi-
tory nerve, this method seems to be more depend-
able22,68,86,93–101. Unlike injection into the cochlear
fluids, the cells are located into the appropriate neural tract
with morphological continuity with the relevant target
cells. Nevertheless, the membranous labyrinth is injured
as with direct injection into the cochlea. Moreover, intra-
neural injection with a syringe needle can damage the mor-
bid, fragile auditory nerve and trigger an inflammatory
reaction along with reactive gliosis around the needle and
transplant102 (see the following sections for further discus-
sions). This method has proved successful in one study22
and offers important proof of principle for clinical transla-
tion, especially from the viewpoint of donor cell selection
(Table 1; Fig. 2A). However, it remains possible that leak-
age of the donor cells outside the cochlea might have
played a predominant role (see below for the details) in
addition to indirect bystander effects that could account for
the observed improvement of the ABRs.
Direct Cell Injection Into or Onto Auditory Nerve With
Preservation of the Membranous Labyrinth. Even without
damaging cochlear structures, cell injection into the
cerebellopontine angle portion of the auditory nerve trunk
through a hole posterior to the mastoid process (the retro-
mastoid region) has not restored auditory nerve func-
tion103–107.
Surprisingly, functional restoration was observed if
donor cells were simply placed onto the surface of the
auditory nerve via the retromastoid route, thus preserving
the integrity of both the nerve and the membranous labyr-
inth (membranous labyrinth preserved [MLP])2 (Fig. 2A,
B) (Table 1). This “surface transplantation” method can be
regarded as a more promising option for cell transplanta-
tion, and it is, thus, considered in more detail in the follow-
ing sections.
What is the Nature of Nerve injury and Degeneration
and How Could Cell Transplantation Work for Specific
Clinical Conditions?
The success of in vivo experiments with animal models is
encouraging, but it is important to understand the biology
that underlies the pathology of nerve degeneration and the
subsequent structural and biochemical environment that
underlies the successful integration of transplanted cells.
This not only informs the optimal technique for cell delivery












Choi et al. (2012)57 i.v. Guinea pig
Pharmacol, local
No Human blood MSC
Yoo et al. (2015)64 i.v. Autoimmune hearing loss
mouse
No Human ADSC
Lang et al. (2016)60 i.v. Mouse
Pharmacol, local
No Mouse and human blood cell
Kil et al. (2016)59 i.v. Guinea pig
Pharmacol, local
No MSC from human placenta
Ma et al. (2016)62 i.t. Congenital deaf albino pig No Human umbilical cord MSC
Lee et al. (2018)61 i.v. Human cases No MSC
Abd El Raouf et al. (2019)56 i.v. Guinea pig
Pharmacol, systemic
No Guinea pig Harderian gland stem
cells
ABR, auditory brainstem responses; ADSC, adipose tissue-derived stem cell; AuN, auditory nerve; BDNF, brain-derived neurotrophic factor; CPA, cere-
bellopontine angle; DPOAE, distortion product otoacoustic emissions; DRGC, dorsal root ganglion cell; ESC, embryonic stem cell; IAM, internal auditory
meatus; iPSC, induced pluripotent stem cell; i.t., intrathecal injection; i.v., intravenous injection; MLI, membranous labyrinth injured; MLP, membranous
labyrinth preserved; MSC, mesenchymal stem cell; NSC, neural stem cell; OEC, olfactory ensheathing cell; RC, Rosenthal’s canal; Ref, reference number; ScM,
the scala media; ScT, the scala tympani; ScV, the scala vestibuli.
* “Donor cell” indicates the provenance of donor cell. Donor cells may have been preconditioned in vitro before transplantation. For example, application of
neural induction for ESC.
# “Pharmacol, local” indicates that pharmacological agents were applied locally to the auditory system. For example, ouabain applied to the round window of
the cochlea.
** “Pharmacol, systemic” indicates application intravenously. For example, ototoxic antibiotics such as kanamycin injected in the tail vein of the host.
Note: Studies using more than one cell delivery routes are repeatedly listed in Table 1. The references in the text and table are listed basically in chronological
order.
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Structural and Biochemical Cues for Cell
Transplantation
Protective Addition. In principle, regenerative medicine should
add new functional elements without causing further dam-
age, following the principle of “protective addition”. This
principle is most effectively met for the auditory nerve by
placing donor cells on the tissue surface2. As discussed
above, all other delivery techniques involve significant tis-
sue damage.
The Scaffold. The scaffold is an indispensable element for the
formation of the nervous system. For example, radial glia
plays a crucial role as the scaffold for cell migration from the
ventricular zone toward the brain surface108,109. Hence, var-
ious artificial scaffolds such as collagen-rich acellular
matrices and matrices such as hydrogel with in vitro
expanded donor cells attached have been intensively inves-
tigated in many neurodegenerative disorders, including
spinal cord injury (SCI) with efforts to overcome various
obstacles including provocation of host immune
responses110–114. Currently, another practical issue to be
solved aiming at clinical translation is the surgical maneu-
verability of artificial materials in the delicate and confined
space of the CNS.
The Scaffold Within: A Natural Autologous cell Scaffold. One of
two successful studies was serendipitous but demonstrated
that an autologous cell scaffold had been spontaneously
formed in collaboration with SCs during the progression of
auditory nerve degeneration. This naturally occurring auto-
logous cell scaffold plays key roles in cell integration as
described below. A number of donor cells incidentally
spilled onto the nerve surface from a hole through which a
syringe needle had been inserted for traditional intra-neural
injection of donor cells. These “leaked” donor cells autono-
mously entered the nerve, gradually transformed into the
bipolar shape characteristic of auditory SGCs in the nerve,
and finally formed synapses with target HCs and cochlear
nucleus cells2 (Fig. 2B and 4). Intriguingly, donor cell
migration and axon elongation apparently recapitulated pro-
cesses observed during development. These processes
include glia-guided migration115 and migration within
GFAP-positive astrocytic, tube-like structures in the rostral
migratory stream116,117. Even residual neurons appeared to
be used as a migration guide118 (Fig. 4D).
Natural Autologous Cell Scaffold—the Astrocyte Outgrowth and
SCs Form a Bridge Between the CNS and PNS.When neurons in
the CNS die, astrocytes react to form the glial scar (the
astrocyte scar), irrespective of the cause, which may be
ischemia, mechanical trauma, irradiation, or genetic disor-
der119–122. In mouse SCI, reactive astrocytes of the glial scar
form characteristic elongated and overlapping processes at
the periphery of the lesion core about a week after the
insult123. In a rat stroke model, reactive astrocyte processes
were apparently longer than in sham rats in the penumbra
even 30 days after ischemic and hemorrhagic stroke124.
After a stab lesion in the cerebral cortex of mice, one subset
of astrocytes directed their processes toward the lesion125.
After injection of iron into mice, reactive astrocytes around
the lesion core extended long and overlapped processes126.
Figure 4. Comparison between intraneural and surface transplan-
tation of cells. (A) Intraneural transplantation of DCs. ABRs before
compression (1), 5 weeks after compression before cell transplan-
tation (2), and 3 months after (3). Arrowhead in panel 3, mono-
phasic positive potential indicating electrical failure of nerve impulse
transmission. I–V, ABR wave I–V. (B) Surface transplantation of
donor cells. ABRs before compression (1), 5 weeks after compres-
sion (2), and 3 months after surface transplantation (3). Note a
significant improvement of ABRs 3 months after surface transplan-
tation (see Sekiya et al., 2015 for more details). (C) Schematic
drawing of fate of intraneurally injected cells. (1) Cell debris mainly
in the site of cell transplantation (large arrow), and a few cells are
seemingly stuck in the gliotic auditory nerve tissue (small arrows).
(2) Large arrow indicates cavity formation (asterisk) in the nerve
due to infusion pressure during injection and the infused cell mass.
Small arrow indicates cell debris around the cavity. (see Sekiya
et al., 2015 for original images). Scale bars: (1), 200 mm; (2) 50
mm. (D) Schematic drawing of various modes of cell migration of
donor cells transplanted on the surface of the auditory nerve (see
Sekiya et al., 2015 for original images). (1) The DCs autonomously
enter the AuN in a chain formation (hollow arrows). CSF, cere-
brospinal fluid in the cerebellopontine angle subarachnoid space. (2)
Within a gliotic auditory nerve, a transplanted cell is intimately
associated with a GFAPþ process (black arrow) derived from the
glial scar and migrated (hollow arrow). (3) three migrating donor
cells (hollow arrows) form chains within GFAPþ sheaths (2 pairs of
black arrows). (4) Migrating transplanted cells (hollow arrows)
associated with neurons (black arrow), possibly for guidance. Scale
bars: (1, 2, 4), 20 mm; (3) 10 mm. Cited from Sekiya et al. (2015) with
publisher’s permission. ABR, auditory evoked brainstem responses;
AuN, auditory nerve; BS, brainstem; CSF, cerebrospinal fluid; DCs,
donor cells; GFAP, glial fibrillary acidic protein.
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Similarly, at the cranial and peripheral nerve roots, such
elongated processes of reactive astrocytes are observed as a
conspicuous tongue-like protrusion toward the periphery, the
astrocyte outgrowth (the AO) (Fig. 3). One clinical study
demonstrated that auditory nerve specimens taken during
VS surgery were gliotic, indicating that reactive astrocytes
had invaded the auditory nerve127. Other than damaged audi-
tory nerve, the AO has been reported in a plethora of diseases
in which motor and sensory neurons die, including amyo-
trophic lateral sclerosis128–133. Electron microscopy shows
that the AO comprises processes of reactive astrocytes of the
glial scar, which have been known as “glial bundles”,
extending from the spinal cord/brainstem128,130,133. It should
be noted that the polarity of the AO plays pivotal roles in cell
migration and axon elongation134.
Normally, astrocytes in the CNS and SCs in the PNS are
apart and mutually exclusive but their mutual repulsion
decreases following motor and sensory neuron death in the
brainstem/spinal cord135. As a result, the distal tip of the AO
extensively apposes with SCs or is directly wrapped by SC
cytoplasm within a common basal lamina133,135. Distally,
SCs form structures called SC columns or bands of Bungner
that can guide regenerating axons back to their targets136.
Thus, a continuous structure, the AO–SC complex, forms
autonomously and can act as an anatomical bridging scaffold
connecting the CNS and the PNS137 (Fig. 2B). In fact, in one
study on the auditory nerve, the AO–SC complex appeared
to be the only continuous scaffold between the PNS and
CNS2.
Furthermore, upon injury, both astrocytes and SCs
become rich sources of pro-regenerative molecules, includ-
ing laminin, N-cadherin neural cell adhesion molecule,
nerve growth factor, BDNF, NT-3, and fibroblast growth
factor, glial cell line-derived neurotrophic factor, artemin,
and vascular endothelial growth factor136,138,139.
Intraneural Injection and Surface Transplantation
It is difficult to compare the different cell transplantation
experiments in the auditory system because the donor cells,
surgical techniques, and animal models are so varied. How-
ever, when intraneural injection and surface transplantation
were compared under the same parameters2, surface trans-
plantation was clearly more successful. There was no ABR
improvement with intraneural transplantation, and the trans-
mission of electrical activity failed to pass the transplanta-
tion site140 (Fig. 4A). Morphological examination revealed a
failure of cell migration with cell debris mainly at the site of
cell transplantation with a few cells stuck in the midst of the
gliotic auditory nerve (Fig. 4C,1). Another finding was cav-
ity formation in the nerve, apparently due to infusion pres-
sure during injection and the large volume of the infused cell
mass that might also have damaged residual host neurons
and vascular networks (Fig. 4C, 2). In contrast, the animals
in which cells were delivered by surface transplantation
demonstrated statistically significant improvement of the
ABRs measured 3 months after cell transplantation (Fig.
4B). Morphologically, various modes of cell migration were
observed as mentioned above (Fig. 4D, 1–4), and synaptic
connections with HCs and the cochlear nucleus cells were
morphologically confirmed (refer to ref. 2 for the original
images).
The Glial Scar, is it Friend or foe?
Emerging evidence challenges the traditional belief that the
glial scar is a physical and molecular barrier to neural regen-
eration141–143. An in vivo experimental study on SCI showed
that regenerating axons skirted around the surface of the glial
scar144, indicating that they can negotiate its surface and
benefit from the structural and chemical cues that it contains.
In unilateral cerebral stroke of the motor cortex in mouse,
axons of the contralesional corticospinal tract normally
sprout into the denervated spinal cord and contribute to
motor functional recovery. In a double knockout of GFAP
and vimentin (the principal genes responsible for glial scar
formation), corticospinal axons only rarely crossed the mid-
line and the reduced astrocytic reactivity led to impaired
neurological recovery142. Another study showed that scar-
forming reactive astrocytes do not only have a protective
function but also promote axonal regrowth after SCI. In two
different transgenic mouse models to either prevent or inhi-
bit glial scar formation, the study showed that there is a
failure in axonal regrowth following removal of reactive
astrocytes in both acute and chronic glial scars141. Reactive
astrocytes in cerebral infarct play a crucial source of a pro-
regenerative molecule, the stromal cell-derived factor 1
(SDF-1)145. Blocking SDF-1 action with a neutralizing anti-
body against a receptor for SDF-1, CXC chemokine receptor
4 (CXCR4), strongly attenuated progenitor migration146,
indicating that SDF-1/CXCR4 promotes migration of stem/
progenitor cells toward the lesion147.
Pro- and Anti-Regenerative Astrocytes
Astrocytes are not homogenous and are composed of at
least five distinct subpopulations, although it is not clear
how each subpopulation responds to different insults in
different locations148–150. Astrocytes not only conform to
different environmental niches but also show different tran-
scriptional changes induced by different types of inju-
ries149,151. In a non-penetrating lateral fluid percussion
brain injury model in adult rats, the morphology of reactive
astrocytes is regionally distinct; those in the injured cortex,
subcortical white matter tracts, and CA3 region of the hip-
pocampus show a distinct morphology with an enlarged cell
body and long intertwined processes, but those in the tha-
lamic nuclei have thicker shorter processes152. Following
experimental occlusion of the middle cerebral artery, reactive
“A2” astrocytes are likely to be protective as they lead to
increased expression of neurotrophic factors and cytokines,
transferring mitochondria to injured neurons143,148,153. In
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contrast, neuroinflammation with systemic endotoxin
lipopolysaccharide injection induces neurotoxic “A1”
astrocytes143,148,153. A recent study reported that such
molecular and functional diversity of astrocytes in the
healthy adult brain depends on cues from neurons through
neuron-derived sonic hedgehog (Shh)154. This is also
another example of glia–neuron interaction (see above).
Thus, it is more likely that there are pro- and anti-
regenerative reactive astrocytes, and further research is
required to identify those subsets of reactive astrocytes that
can aid and contribute to axon elongation efficiently for
auditory nerve regeneration.
What is the Ideal Animal Experimental Model?
Studies of the auditory nerve require animal models in which
the auditory nerve is selectively, quantifiably, and reprodu-
cibly damaged without confounding factors such as conco-
mitant HC damage.
In pharmacological models, to induce auditory
nerve degeneration, ouabain is most commonly
used22,57,59,60,65,66,70,75,76,82,85,86,93,96,100,103. However,
with this approach, SGNs are hard to damage reproducibly
to avoiding “sudden and all-or-none type cell death”. It
is technically difficult to titrate the dose, so ouabain
treatments destroy nearly all SGNs in most of the
studies60,85,86,93,96,155–158. This makes it hard to assess any
further damage that may occur through surgical intervention.
Instead, clinically relevant animal experimental models
of neurodegenerative disorders, including hearing loss,
should ideally involve a reproducible, “intermediate
degree” of stable injury to reflect the gradual progression
of tissue degeneration and a suitable opportunity to sys-
tematically test potential therapies. In fact, this critical
issue has long been discussed when creating animal mod-
els of SCI159.
Ouabain is usually applied to the round window in the
middle ear. It enters the cochlea across the round window
membrane and is diluted in the perilymph of the scala tym-
pani before reaching the SGN through Schuknecht’s canali-
culae perforantes3,160. Pharmacological agents, including
ouabain, that are applied even locally to the cochlea gener-
ally diffuse throughout the cochlear fluid space in an uncon-
trolled manner and tend to affect not only auditory neurons
but also HCs158,161. Moreover, the effect of ouabain is dif-
ferent between species; ouabain selectively destroys SGNs
in gerbils and mice, whereas in guinea pigs, it preferentially
damages HCs158. In rats, if high doses applied to the round
window are not sufficiently diluted, then both HCs and SGN
can be damaged158.
Ouabain is a potent inhibitor of the ubiquitous Naþ-Kþ
pump162, which maintains a low Naþ and high Kþ concen-
tration within most cells to ensure their excitability and to
provide the driving force for the transport of glucose, amino
acids, and other nutrients into the cell162,163. Thus, a caveat
with ouabain is that it may affect not only neurons but also
cells in the surrounding epithelial, connective, and muscle
tissues. This also applies in systemic administration of phar-
macological agents164. Thus, the majority of animal models
are not ideal for clinical translation.
In contrast, if mechanical compression is applied to the
CNS portion of the auditory nerve, it can produce selective,
“intermediate” degree of degeneration of auditory neurons
with HCs preserved2,165,166 (Fig. 1B, l, 4A, B). This leads
to transneuronal death of CNS cells (cochlear nucleus cells)
and formation of a protruded bundle of reactive astrocytes of
the glial scar (the AO), which plays a crucial role with distal
Schwann cell columns for auditory nerve regeneration as
elucidated above (Figs. 2B, 3B, 4). Unique to this model,
the transneuronal degeneration of cochlear nucleus cells
(Fig. 1B, k) can be quantitatively analyzed165,167,168.
Mechanical compression is thus likely to be the most realis-
tic model for the clinical conditions that lead to auditory
nerve degeneration.
Donor Cells for Auditory Nerve Regeneration
Cell Source. Selection and preparation of donor cells are not
the focus of this review, but they are critical issues because
the cells must be competent to respond to regenerative cues
within the damaged tissue.
As depicted in Table 1, embryonic stem cells (ESC) and
neural stem cells (NSC) were most frequently used as xeno-
grafts or allografts after preconditioning in vitro with diverse
factors such as bFGF, BMP4, and the bHLH transcription
factor neurogenin 268,80,93,100,169. These approaches carry a
greater risk of immune rejection compared with autologous
transplantation170. Even using autologous-induced pluripo-
tent stem cells (iPSCs) as donor cells, immune rejection can
be an issue170–172, despite major histocompatibility complex
matching173. Furthermore, the phenotypes of individual
iPSCs are not entirely predictable, and preconditioning can
be complex, time-consuming, and expensive174–177.
Human cells, particularly autologous human cells, are the
most likely candidates for clinical translation and those
derived from mesenchymal stem cells and adipose tissue-
derived stem cells are being studied intensively as donor
cells in human disease178–184. Tissue-specific autologous
stem cells are naturally strong candidates because they are
more closely adapted to the host environment185,186. The
human inner ear contains endogenous adult stem cells, as
has been shown in other organs187,188,189, although their
potential at the clinical level is not yet clear.
Bipolarity, a Key Requisite as Donor Cells for Auditory Nerve
Regeneration. Auditory neurons are bipolar, and donor cells
must connect both peripherally with HCs and centrally with
cochlear nucleus cells. Table 1 shows that functional recov-
ery of the auditory nerve has been achieved only in two
studies, one with human ESCs22 and the other with a mouse
cell line2. In both cases, the donor cells adopted a bipolar
phenotype2,22. The ESCs were conditioned as otic
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progenitors by simulating the initial, developmental specifi-
cation of the otic placode with sequential application of
selected factors, including NT-3, BDNF, bFGF, and Shh22.
The mouse cells were from a conditionally immortal mouse
otic neuroblast cell line, US/VOT-N33, derived from a
mouse otocyst (inner ear anlage)190. They show that ontoge-
netic-stage/region-restricted precursors can be successfully
integrated into the host tissue, which has also been shown in
a study of retinal regeneration191.
Ultimately, the selection of appropriate donor cells must
be made in the context of the animal model most closely
allied to the clinical application. It cannot be assumed that a
given cell type would be equally effective with both intra-
neural injection and cell surface delivery because the bio-
chemical cues encountered from the damaged tissue may be
different. Thus, there is a need for more systematic research
with a number of potential donor cell types in carefully
controlled animal models. This is recognized more generally
in cell transplantation to address a number of technical hur-
dles, not least those of phenotype instability, cost versus
benefit, and ethical issues170,183.
A Minimally Invasive Technique for Cell
Transplantation
Endoscopic surface transplantation.Minimal invasiveness of cell
delivery is an indispensable requisite for clinical translation192.
Endoscopymay fulfill this requirement most efficiently (Fig. 5).
It has long been used in clinical otorhinolaryngology, has been
reported in neurosurgical procedures since the 1970s193,194, and
its safe maneuverability in the CPA has been established195,196.
Surface transplantation of donor cells to the auditory
nerve can be done with an endoscope introduced intracra-
nially through a single keyhole in the retromastoid area. It
could be applied to diseases such as auditory neuropathic
hearing loss in neuropathies and head trauma (Fig. 5A),
VS immediately after tumor removal (Fig. 5B), and VS fol-
lowing RT (Fig. 5C). This simple procedure requires only
local anesthesia under sedation, and it is, thus, applicable to
physically more sensitive patients, including the elderly.
Surface transplantation has several other advantages.
Excessive numbers of cells are not required to compensate
for the very high rates of donor cell death as observed in
Figure 5. Endoscopic surface transplantation of donor cells. (A) In patients with non-tumorous auditory neuropathic hearing loss, an
endoscope can be introduced in the cerebellopontine angle cistern and DCs placed onto the AuN. Normal facial nerve (VII) and vestibu-
locochlear nerve (VIII) are shown in the left upper corner of the panel. (B) In open surgery for larger VS, following tumor removal (left),
donor cells can be placed on the surface of the AuN. The posterior wall of the internal auditory meatus is drilled to expose the tumor
entirely. (C) In radiotherapy for small to medium-sized VS (arrows), a similar approach shown in A can be undertaken immediately after
treatment. DCs are placed both on the distal side of the tumor through the internal auditory meatus (shown in this figure) and on its medial
side if possible (not shown here). The dotted line indicates tumor shrinkage after radiotherapy. Regenerated bipolar neurons (dotted line)
are shown in the nerve in each panel. AuN, auditory nerve; CN, cochlear nucleus cells; Cr, cerebellum; DC, donor cell; En, endoscope; HC,
hair cell; IAM, internal auditory meatus; kh, keyhole; Rt, retractor; VS, vestibular schwannoma.
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intraparenchymal injection197 because donor cells appar-
ently autonomously enter the host tissue in proportion to the
demand and capacity of the host environment2. Moreover, in
contrast to intraneural injection, donor cells transplanted
onto the nerve are immediately nourished by cerebrospinal
fluid, which is a very rich source of nutrients including pro-
teins, ions, lipids, hormones, cholesterol, glucose and meta-
bolites, and pro-regenerative molecules such as BDNF and
IGF-2198,199, before they establish a link to the blood supply.
In transplantation experiments of Parkinson’s disease, most
dopamine neurons injected into the brain died due to apop-
tosis within the first 24 h of transplantation200, and subse-
quently, more than 90% of transplanted neurons died by the
end of a typical several week transplantation study201,202. In
rats, more than 1 week is required after transplantation
before sufficient neovascularization is established between
the host and transplants203,204. Until then, the intraparenchy-
mally transplanted cells suffer insufficient nutrients diffus-
ing from host vessels located outside the graft perimeter,
resulting in apoptotic cell death (see the sections above).
It is worth noting that “surface transplantation” of donor
cells is distinct from “stem cell sheet technology” such as
that explored in heart, kidney, and liver disorders205,206. In
surface transplantation for auditory nerve regeneration, a
uniformly molded cell sheet manufactured before cell trans-
plantation cannot be applied to the target area. On the con-
trary, to facilitate the integration of donor cells into the host,
it is important to drop them freely into the narrow spaces
within the irregular and complex contours of the tissue
surface.
Conclusion
We conclude that there is great potential for clinical trans-
lation of cell transplantation in the auditory nerve. Proof of
principle has been established; appropriate clinical tech-
niques are available, and there is considerable theoretical
support from wide-ranging studies on neurodegeneration and
tissue repair. Auditory nerve damage may occur as a result of
neuropathies, intracranial mass lesions, head trauma, and
even therapeutic intervention. The finding that donor cells
placed on the surface of the gliotic auditory nerve autono-
mously entered the nerve tissue, migrated, and functionally
integrated into the host neural circuit makes clinical surgery
much more realistic2. For clinical translation, endoscopy
provides the best way to deliver viable cells to the tissue
surface with minimal damage to residual functional elements
in the nerve.
Whilst proof of principle is an important step, there is
clearly a need for focused animal experiments that recreate
the combination of approaches necessary for clinical appli-
cation. “From the bench to the clinic” is a slogan that has
been repeated also in regenerative medicine. Now it can be
accomplished if an appropriate cell transplantation method is
applied to humans, choosing potent human stem cells or
human cochlear precursors207,208 that may or may not be
conditioned to achieve integration.
Notably, the auditory nerve holds an advantageous and
suitable position for cell transplantation therapy because
HCs, auditory neurons, and cochlear nucleus cells are
aligned over a relatively short distance209,210. This contrasts
with the recovery of the injured pyramidal tract in SCI,
which involves not only axon sprouting but also recruiting
endogenous relay neurons211,212.
Finally, transdisciplinary combinations with regenerative
studies for both auditory nerve and HCs would pave a new
path for more widespread treatment of DHL and even for a
number of other neurodegenerative conditions.
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